ALNYLAM PHARMACEUTICALS, INC.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $440,000.00 expenses · posted Apr 21, 2025

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare coverage of home infusion; issues related to the implementation of the Inflation Reduction Act.

Veterans

Issues related to veterans healthcare.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.